273 related articles for article (PubMed ID: 12083482)
1. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
[TBL] [Abstract][Full Text] [Related]
2. YD-3, a novel inhibitor of protease-induced platelet activation.
Wu CC; Huang SW; Hwang TL; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 2000 Jul; 130(6):1289-96. PubMed ID: 10903968
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
4. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets.
Wu CC; Wang WY; Wei CK; Teng CM
Thromb Haemost; 2011 Jan; 105(1):88-95. PubMed ID: 21057701
[TBL] [Abstract][Full Text] [Related]
5. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets.
Cumashi A; Ansuini H; Celli N; De Blasi A; O'Brien PJ; Brass LF; Molino M
Thromb Haemost; 2001 Mar; 85(3):533-8. PubMed ID: 11307827
[TBL] [Abstract][Full Text] [Related]
7. The role of PAR4 in thrombin-induced thromboxane production in human platelets.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Teng CM
Thromb Haemost; 2003 Aug; 90(2):299-308. PubMed ID: 12888878
[TBL] [Abstract][Full Text] [Related]
8. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
11. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PAR4 signaling mediates ethanol-induced attenuation of platelet function in vitro.
Kasuda S; Sakurai Y; Shima M; Morimura Y; Kudo R; Takeda T; Ishitani A; Yoshioka A; Hatake K
Alcohol Clin Exp Res; 2006 Sep; 30(9):1608-14. PubMed ID: 16930224
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
Burke FM; Warnock M; Schmaier AH; Mosberg HI
Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
[TBL] [Abstract][Full Text] [Related]
14. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
15. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin G activates protease-activated receptor-4 in human platelets.
Sambrano GR; Huang W; Faruqi T; Mahrus S; Craik C; Coughlin SR
J Biol Chem; 2000 Mar; 275(10):6819-23. PubMed ID: 10702240
[TBL] [Abstract][Full Text] [Related]
17. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
18. Heparin inhibits neutrophil-induced platelet activation via cathepsin G.
Ferrer-Lopez P; Renesto P; Prevost MC; Gounon P; Chignard M
J Lab Clin Med; 1992 Mar; 119(3):231-9. PubMed ID: 1541873
[TBL] [Abstract][Full Text] [Related]
19. Interference of recombinant eglin C, a proteinase inhibitor extracted from leeches, with neutrophil-mediated platelet activation.
Renesto P; Ferrer-Lopez P; Chignard M
Lab Invest; 1990 Apr; 62(4):409-16. PubMed ID: 2159081
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil elastase potentiates cathepsin G-induced platelet activation.
Selak MA
Thromb Haemost; 1992 Nov; 68(5):570-6. PubMed ID: 1333649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]